{"product_id":"iqvia-pestle-analysis","title":"IQVIA PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSkip the Research. Get the Strategy.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eGain a strategic advantage with our PESTLE Analysis of IQVIA—uncover how political shifts, regulatory pressures, economic trends, and tech advances are shaping its growth and risks; buy the full report for detailed, actionable insights tailored for investors, consultants, and strategists.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImpact of US Drug Pricing Legislation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Inflation Reduction Act, through 2025, has led to a 20–30% shift in client R\u0026amp;D prioritization toward biologics as manufacturers seek longer exclusivity against new Medicare price caps; IQVIA sees demand for biologics-focused evidence rising ~25% year-over-year. IQVIA must expand market-access modeling and pricing analytics—clients expect support in Medicare Part B\/Part D negotiation scenarios where potential rebates could cut net prices by up to 40%. IQVIA’s services now emphasize lifecycle strategy, real-world evidence, and value-based contracting tools to quantify savings and secure favorable access under tightened pricing rules.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical Tensions and the Biosecure Act\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHeightened US-China tensions have spurred measures like the Biosecure Act, which bars federal contracts with some Chinese biotech vendors, accelerating reshoring of sensitive R\u0026amp;D and clinical operations.\u003c\/p\u003e\n\u003cp\u003eAs a US-based global leader, IQVIA (2024 revenue $9.3B) is well positioned to capture demand as sponsors de-risk supply chains and move trials to politically aligned regions.\u003c\/p\u003e\n\u003cp\u003eShift toward domestic\/European sites boosts need for IQVIA’s site management and labs, supporting growth in service bookings and higher-margin clinical operations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Regulatory Harmonization Initiatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical efforts to harmonize clinical trial approvals—driven by ICH, EMA-US collaborations and WHO initiatives—are reducing duplication and could cut multi-jurisdiction approval time by an estimated 20–30%, encouraging IQVIA to scale integrated global regulatory affairs services now representing ~15% of its commercial offerings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Healthcare Spending and Subsidies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePublic health budgets in OECD countries face tightness—public health expenditure growth slowed to 1.8% in 2023—driving payers to demand stricter cost-effectiveness; IQVIA uses RWE to quantify value and support HTA submissions for high-cost therapies.\u003c\/p\u003e\n\u003cp\u003eWith governments like India and parts of Europe expanding universal coverage, population health programs grow; IQVIA can consult on large-scale implementations using its data platforms and analytics.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOECD public health spending growth 1.8% (2023)\u003c\/li\u003e\n\u003cli\u003eRWE-driven HTA support reduces reimbursement risk\u003c\/li\u003e\n\u003cli\u003eUniversal coverage expansions create large-scale consulting demand\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTrade Policies and Data Sovereignty\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIncreasing protectionist trade policies and strict data residency rules are pushing IQVIA to localize storage and processing; EU data localization proposals and India’s Personal Data Protection Bill threaten cross-border clinical-data flows, impacting ~30% of global trial sites. IQVIA must invest in regional data centers and compliance frameworks—recently committing hundreds of millions in capex to expand local infrastructure.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~30% of trial sites affected\u003c\/li\u003e\n\u003cli\u003eHundreds of millions USD in regional capex\u003c\/li\u003e\n\u003cli\u003eEU and India digital sovereignty driving localization\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIQVIA $9.3B amid 25% biologics evidence surge; 30% sites hit, hundreds-M capex\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUS IRA shifts R\u0026amp;D 20–30% to biologics; IQVIA sees ~25% YoY rise in biologics evidence demand; 2024 revenue $9.3B. OECD health spend growth 1.8% (2023); HTA pressure rises. ~30% of trial sites hit by data-localization; hundreds of millions USD capex for regional infrastructure.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIQVIA 2024 rev\u003c\/td\u003e\n\u003ctd\u003e$9.3B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiologics demand rise\u003c\/td\u003e\n\u003ctd\u003e~25% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOECD health spend growth (2023)\u003c\/td\u003e\n\u003ctd\u003e1.8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSites affected\u003c\/td\u003e\n\u003ctd\u003e~30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegional capex\u003c\/td\u003e\n\u003ctd\u003ehundreds of millions USD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how external macro-environmental factors uniquely affect IQVIA across six dimensions—Political, Economic, Social, Technological, Environmental, and Legal—backed by current data and trends to identify threats and opportunities for executives, consultants, and entrepreneurs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, visually segmented PESTLE snapshot of IQVIA that’s ready to drop into presentations or sharing—simplifying external risk discussion and enabling quick alignment across teams during planning sessions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiotechnology Funding and Venture Capital Recovery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBy end-2025 venture funding into biotech stabilized at about $35bn annually after 2023–24 volatility, enabling many small and mid-sized firms to restart delayed trials; IQVIA reported CRO revenue up roughly 6–8% Y\/Y in 2025 as trial activity recovered. The company’s growth remains tightly linked to capital availability for innovation-led firms, which often outsource due to limited in-house infrastructure and accounted for an increased share of IQVIA’s bookings in 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharma R\u0026amp;D Outsourcing Trends\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLarge pharma are shifting to variable cost models to shield margins from 2024–25 global inflation; 68% of top 50 pharma reported increasing outsourced spend in 2024, boosting demand for IQVIA services.\u003c\/p\u003e\n\u003cp\u003eOutsourcing of clinical monitoring, data management and commercial sales grew ~12% YoY in 2024, favoring IQVIA as clients offload non-core functions.\u003c\/p\u003e\n\u003cp\u003eMove from transactional contracts to strategic partnerships has increased multi-year agreements; IQVIA’s contracted backlog rose ~9% in 2024, supporting steadier long-term revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency Exchange Rate Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAs a US dollar reporter, IQVIA is exposed to volatility in the Euro, Yen and Pound; a 10% depreciation of the Euro versus the dollar in 2023 would have cut reported revenue from Euro-denominated contracts by roughly the same magnitude on translation. Economic instability in Europe and Japan has driven FX swings—EUR\/USD ranged 0.95–1.11 in 2023–2024—reducing translated revenue and operating margins. IQVIA uses layered hedging (forwards, options) and regional pricing adjustments to cushion impacts, yet persistent currency headwinds contributed to FX-related revenue headwinds reported in FY2024 results.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLabor Market Dynamics and Professional Wages\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe specialized nature of clinical research and data science has driven sustained wage inflation for high-skilled life sciences professionals, with US median clinical data scientist salaries rising ~18% from 2019–2024 to about $128,000 and pharma biostatistician pay up ~22% to ~$145,000 in 2024.\u003c\/p\u003e\n\u003cp\u003eIQVIA must balance attracting top-tier talent against pressure to keep technology and service pricing competitive as labor costs squeeze margins; average industry bill rates grew ~12% CAGR 2020–2024.\u003c\/p\u003e\n\u003cp\u003eDeclining labor participation in key markets and a tight STEM talent pool have pushed IQVIA to invest in automation (R\u0026amp;D in AI increasing by ~30% YoY for major CROs) and expand offshore delivery centers to reduce onshore labor cost exposure.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh-skilled wage inflation: clinical data scientist +18% (2019–2024), biostatistician +22% (2024)\u003c\/li\u003e\n\u003cli\u003eIndustry bill rates: ~12% CAGR (2020–2024)\u003c\/li\u003e\n\u003cli\u003eAutomation\/AI R\u0026amp;D spend growth: ~30% YoY among leading CROs\u003c\/li\u003e\n\u003cli\u003eOffshoring used to lower onshore labor costs and manage margins\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Inflation and Interest Rates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eWhile central bank rates have begun stabilizing in 2024—US Fed at 5.25–5.50% and ECB around 3.75%—cumulative inflation continues to raise clinical trial supply and logistics costs, with pharmaceutical logistics up ~8–12% YoY in 2023–24.\u003c\/p\u003e\n\u003cp\u003eIQVIA’s contracts often include inflation-adjustment clauses, but rapid price spikes for specialized equipment (some OEM prices up 10–20% since 2022) can compress margins on fixed-fee studies.\u003c\/p\u003e\n\u003cp\u003eThe macro environment also slows client commitments to multi-year, multi-million-dollar technology transformations; global healthcare IT spending growth eased to ~6% in 2024, delaying large procurement cycles.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStable policy rates but persistent inflation-driven cost pressures\u003c\/li\u003e\n\u003cli\u003eInflation clauses help but don’t fully offset 10–20% equipment price rises\u003c\/li\u003e\n\u003cli\u003eSlower client IT spend growth (~6% in 2024) delays big multi-year contracts\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiotech VC steadies at $35B; CROs grow 6–8% as outsourcing rises amid cost pressures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEconomic factors: biotech VC stabilized ~ $35bn\/year by end-2025, CRO revenue +6–8% Y\/Y in 2025 as trials resumed; top-50 pharma increased outsourced spend (68% in 2024), driving demand. Wage inflation pressured margins (clinical data scientist +18% 2019–24; biostatistician +22% 2024), while FX volatility (EUR\/USD 0.95–1.11 in 2023–24) and equipment price rises (10–20% since 2022) created headwinds.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiotech VC (2025)\u003c\/td\u003e\n\u003ctd\u003e$35bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIQVIA CRO rev growth (2025)\u003c\/td\u003e\n\u003ctd\u003e+6–8% Y\/Y\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop-50 pharma outsourcing (2024)\u003c\/td\u003e\n\u003ctd\u003e68%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical data scientist pay (2019–24)\u003c\/td\u003e\n\u003ctd\u003e+18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiostatistician pay (2024)\u003c\/td\u003e\n\u003ctd\u003e+22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEUR\/USD range (2023–24)\u003c\/td\u003e\n\u003ctd\u003e0.95–1.11\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEquipment price rise (since 2022)\u003c\/td\u003e\n\u003ctd\u003e10–20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eIQVIA PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact IQVIA PESTLE Analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use for strategic planning or investment review.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751218852217,"sku":"iqvia-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/iqvia-pestle-analysis.png?v=1772228958","url":"https:\/\/growthsharematrix.com\/products\/iqvia-pestle-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}